NEUBASE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.378 USD | -3.20% |
|
0.00% | -48.93% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâs programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâs disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -48.93% | 1.39M | |
| +41.79% | 54.04B | |
| +47.13% | 41.96B | |
| -0.56% | 41.92B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| -21.51% | 19B | |
| +6.92% | 13B | |
| +29.60% | 12.28B | |
| +24.91% | 12.19B |
